메뉴 건너뛰기




Volumn 5, Issue 4, 2015, Pages 378-398

Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy

Author keywords

EGFR1; HER2

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 1 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MACROGOL 20000; MULTIVALENT ANTIBODY COMPRISED OF NANOBODY AND AFFIBODY; NANOBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; HYBRID PROTEIN;

EID: 84924291069     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10084     Document Type: Article
Times cited : (63)

References (74)
  • 1
    • 0034600849 scopus 로고    scopus 로고
    • The ErbB signaling network: receptor heterodimerization in development and cancer
    • Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO. 2000; 19: 3159-67.
    • (2000) EMBO. , vol.19 , pp. 3159-3167
    • Olayioye, M.A.1    Neve, R.M.2    Lane, H.A.3
  • 2
    • 17844372539 scopus 로고    scopus 로고
    • Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
    • Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445-59.
    • (2005) J Clin Oncol. , vol.23 , pp. 2445-2459
    • Baselga, J.1    Arteaga, C.L.2
  • 4
    • 39649123058 scopus 로고    scopus 로고
    • Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk
    • Yoshida T, Okamoto I, Okabe T, et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer. 2008; 122 (7): 1530-8.
    • (2008) Int J Cancer. , vol.122 , Issue.7 , pp. 1530-1538
    • Yoshida, T.1    Okamoto, I.2    Okabe, T.3
  • 5
    • 84867372753 scopus 로고    scopus 로고
    • Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
    • van de Water JAJM, Bagci-Onder T, Agarwal AS, et al. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci U S A. 2012; 109 (41): 16642-7.
    • (2012) Proc Natl Acad Sci U S A. , vol.109 , Issue.41 , pp. 16642-16647
    • van de Water, J.A.J.M.1    Bagci-Onder, T.2    Agarwal, A.S.3
  • 6
    • 60449094950 scopus 로고    scopus 로고
    • Protein and lipid kinase inhibitors as targeted anticancer agents of the RAS/RAF/MEK and PI3K/PKB pathways
    • García-Echeverría C. Protein and lipid kinase inhibitors as targeted anticancer agents of the RAS/RAF/MEK and PI3K/PKB pathways. Purinergic Signal. 2009; 5 (1): 117-25.
    • (2009) Purinergic Signal. , vol.5 , Issue.1 , pp. 117-125
    • García-Echeverría, C.1
  • 7
    • 0037099532 scopus 로고    scopus 로고
    • Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action
    • Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002; 62 (14): 4132-41.
    • (2002) Cancer Res. , vol.62 , Issue.14 , pp. 4132-4141
    • Yakes, F.M.1    Chinratanalab, W.2    Ritter, C.A.3
  • 8
    • 2342591455 scopus 로고    scopus 로고
    • The discovery of receptor tyrosine kinases: targets for cancer therapy
    • Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4: 361-70.
    • (2004) Nat Rev Cancer. , vol.4 , pp. 361-370
    • Gschwind, A.1    Fischer, O.M.2    Ullrich, A.3
  • 9
    • 0034722889 scopus 로고    scopus 로고
    • The EGF receptor family as targets for cancer therapy
    • Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19: 6550-65.
    • (2000) Oncogene. , vol.19 , pp. 6550-6565
    • Mendelsohn, J.1    Baselga, J.2
  • 10
    • 0024337144 scopus 로고
    • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    • Slamon DJ, Godolphin W, Holt JA, el al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-12.
    • (1989) Science. , vol.244 , pp. 707-712
    • Slamon, D.J.1    Godolphin, W.2    Holt, J.A.3    el, al.4
  • 11
    • 84878926256 scopus 로고    scopus 로고
    • HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
    • Dent S, Oyan B, Honig A, et al. HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials. Cancer Treat Rev. 2013; 39: 622-31.
    • (2013) Cancer Treat Rev. , vol.39 , pp. 622-631
    • Dent, S.1    Oyan, B.2    Honig, A.3
  • 12
    • 0037699294 scopus 로고    scopus 로고
    • Strategies to target HER2/neu overexpression for cancer therapy
    • Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat. 2003; 6: 129-36.
    • (2003) Drug Resist Updat. , vol.6 , pp. 129-136
    • Chen, J.S.1    Lan, K.2    Hung, M.C.3
  • 13
    • 19044380618 scopus 로고    scopus 로고
    • Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    • Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2: 127-37.
    • (2002) Cancer Cell. , vol.2 , pp. 127-137
    • Agus, D.B.1    Akita, R.W.2    Fox, W.D.3
  • 14
    • 0032127350 scopus 로고    scopus 로고
    • Recombinant Humanized Anti-HER2 Antibody (HerceptinTM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts
    • Baselga J, Norton L, Albanell J, et al. Recombinant Humanized Anti-HER2 Antibody (HerceptinTM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts. Cancer Res. 1998; 58: 2825-31.
    • (1998) Cancer Res. , vol.58 , pp. 2825-2831
    • Baselga, J.1    Norton, L.2    Albanell, J.3
  • 15
    • 33846566408 scopus 로고    scopus 로고
    • Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
    • Reid A, Vidal L, Shaw H, et al. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007; 43: 481-9.
    • (2007) Eur J Cancer. , vol.43 , pp. 481-489
    • Reid, A.1    Vidal, L.2    Shaw, H.3
  • 16
    • 58249101005 scopus 로고    scopus 로고
    • The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) Rationale for Combining with EGFR/HER2 Inhibitors
    • Huang F, Greer A, Hurlburt W, et al. The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) Rationale for Combining with EGFR/HER2 Inhibitors. Cancer Res. 2009; 69: 161-70.
    • (2009) Cancer Res. , vol.69 , pp. 161-170
    • Huang, F.1    Greer, A.2    Hurlburt, W.3
  • 17
    • 34250647865 scopus 로고    scopus 로고
    • In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas
    • Larbouret C, Robert B, Navarro-Teulon I, et al. In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas. Clin Cancer Res. 2007; 13: 3356-62.
    • (2007) Clin Cancer Res. , vol.13 , pp. 3356-3362
    • Larbouret, C.1    Robert, B.2    Navarro-Teulon, I.3
  • 18
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
    • Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2006; 355: 2733-43.
    • (2006) N Engl J Med. , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 19
    • 33747855481 scopus 로고    scopus 로고
    • Comparing antibody and small-molecule therapies for cancer
    • Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6: 714-27.
    • (2006) Nat Rev Cancer. , vol.6 , pp. 714-727
    • Imai, K.1    Takaoka, A.2
  • 20
    • 68949212307 scopus 로고    scopus 로고
    • 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging
    • Liu Z, Niu G, Wang F, et al. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009; 36: 1483-94.
    • (2009) Eur J Nucl Med Mol Imaging. , vol.36 , pp. 1483-1494
    • Liu, Z.1    Niu, G.2    Wang, F.3
  • 21
    • 62149129236 scopus 로고    scopus 로고
    • Therapeutic antibodies: successes, limitations and hopes for the future
    • Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009; 157 (2): 220-33.
    • (2009) Br J Pharmacol. , vol.157 , Issue.2 , pp. 220-233
    • Chames, P.1    Van Regenmortel, M.2    Weiss, E.3
  • 22
    • 0037143806 scopus 로고    scopus 로고
    • Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
    • Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002; 100 (6): 690-7.
    • (2002) Int J Cancer. , vol.100 , Issue.6 , pp. 690-697
    • Dreier, T.1    Lorenczewski, G.2    Brandl, C.3
  • 23
    • 28944434529 scopus 로고    scopus 로고
    • Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
    • Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006; 43: 763-71.
    • (2006) Mol Immunol. , vol.43 , pp. 763-771
    • Offner, S.1    Hofmeister, R.2    Romaniuk, A.3
  • 25
    • 77953653252 scopus 로고    scopus 로고
    • Antibody fragments Hope and hype
    • Nelson AL. Antibody fragments Hope and hype. mAbs. 2010; 2 (1): 77-83.
    • (2010) mAbs. , vol.2 , Issue.1 , pp. 77-83
    • Nelson, A.L.1
  • 26
    • 0037102973 scopus 로고    scopus 로고
    • Anti-idiotypic protein domains selected from protein A-based affibody libraries
    • Eklund M, Axelsson L, Uhlen M, et al. Anti-idiotypic protein domains selected from protein A-based affibody libraries. Proteins. 2002; 48 (3): 454-62.
    • (2002) Proteins. , vol.48 , Issue.3 , pp. 454-462
    • Eklund, M.1    Axelsson, L.2    Uhlen, M.3
  • 27
    • 78651464824 scopus 로고    scopus 로고
    • Affibody-based nanoprobes for HER2-expressing cell and tumor imaging
    • Gao J, Chen K, Miao Z, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011; 32: 2141-8.
    • (2011) Biomaterials. , vol.32 , pp. 2141-2148
    • Gao, J.1    Chen, K.2    Miao, Z.3
  • 29
    • 77954034976 scopus 로고    scopus 로고
    • Downregulation of EGFR by a novel multivalent nanobody-liposome platform
    • Oliveira S, Schiffelers RM, Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010; 145: 165-75.
    • (2010) J Control Release. , vol.145 , pp. 165-175
    • Oliveira, S.1    Schiffelers, R.M.2    Veeken, J.3
  • 30
    • 35348819390 scopus 로고    scopus 로고
    • Properties, production, and applications of camelid single-domain antibody fragments
    • Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007; (1): 13-22.
    • (2007) Appl Microbiol Biotechnol. , Issue.1 , pp. 13-22
    • Harmsen, M.M.1    De Haard, H.J.2
  • 31
    • 80052030449 scopus 로고    scopus 로고
    • A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth
    • Roovers RC, Vosjan MJWD, Laeremans T, et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011; 129 (8): 2013-24.
    • (2011) Int J Cancer. , vol.129 , Issue.8 , pp. 2013-2024
    • Roovers, R.C.1    Vosjan, M.J.W.D.2    Laeremans, T.3
  • 32
    • 55549120512 scopus 로고    scopus 로고
    • Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line
    • Ekerljung L, Lindborg M, Gedda L, et al. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Biochem Biophys Res Commun. 2008; 377 (2): 489-94.
    • (2008) Biochem Biophys Res Commun. , vol.377 , Issue.2 , pp. 489-494
    • Ekerljung, L.1    Lindborg, M.2    Gedda, L.3
  • 33
    • 70350561680 scopus 로고    scopus 로고
    • Engineering and characterization of a bispecific HER2× EGFR-binding affibody molecule
    • Friedman M, Lindström S, Ekerljung L, et al. Engineering and characterization of a bispecific HER2× EGFR-binding affibody molecule. Biotechnol Appl Biochem. 2009; 54 (2): 121-31.
    • (2009) Biotechnol Appl Biochem. , vol.54 , Issue.2 , pp. 121-131
    • Friedman, M.1    Lindström, S.2    Ekerljung, L.3
  • 34
    • 78651464824 scopus 로고    scopus 로고
    • Affibody-based nanoprobes for HER2-expressing cell and tumor imaging
    • Gao J, Chen K, Miao Z, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011; 32: 2141-8.
    • (2011) Biomaterials. , vol.32 , pp. 2141-2148
    • Gao, J.1    Chen, K.2    Miao, Z.3
  • 35
    • 33646261864 scopus 로고    scopus 로고
    • Tumor imaging using a picomolar affinity HER2 binding affibody molecule
    • Orlova A, Magnusson M, Eriksson TLJ, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006; 66: 4339-48.
    • (2006) Cancer Res. , vol.66 , pp. 4339-4348
    • Orlova, A.1    Magnusson, M.2    Eriksson, T.L.J.3
  • 36
    • 10644228142 scopus 로고    scopus 로고
    • Efficient cancer therapy with a nanobody-based conjugate
    • Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004; 64 (8): 2853-7.
    • (2004) Cancer Res. , vol.64 , Issue.8 , pp. 2853-2857
    • Cortez-Retamozo, V.1    Backmann, N.2    Senter, P.D.3
  • 37
    • 43249091515 scopus 로고    scopus 로고
    • SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression
    • Huang L, Gainkam LOT, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008, 10 (3): 167-75.
    • (2008) Mol Imaging Biol , vol.10 , Issue.3 , pp. 167-175
    • Huang, L.1    Gainkam, L.O.T.2    Caveliers, V.3
  • 38
    • 4644247278 scopus 로고    scopus 로고
    • Selection and characterization of HER2/neu-binding affibody ligands
    • Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel. 2004; 17 (5): 455-62.
    • (2004) Protein Eng Des Sel. , vol.17 , Issue.5 , pp. 455-462
    • Wikman, M.1    Steffen, A.C.2    Gunneriusson, E.3
  • 39
    • 44149088593 scopus 로고    scopus 로고
    • Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT
    • Gainkam LOT, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49 (5): 788-95.
    • (2008) J Nucl Med. , vol.49 , Issue.5 , pp. 788-795
    • Gainkam, L.O.T.1    Huang, L.2    Caveliers, V.3
  • 40
    • 22344445345 scopus 로고    scopus 로고
    • In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics
    • Steffen AC, Wikman M, Tolmachev V, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm. 2005; 20 (3): 239-48.
    • (2005) Cancer Biother Radiopharm. , vol.20 , Issue.3 , pp. 239-248
    • Steffen, A.C.1    Wikman, M.2    Tolmachev, V.3
  • 41
    • 84869110616 scopus 로고    scopus 로고
    • The HER2-Binding Affibody Molecule (ZHER2: 342) 2 Increases Radiosensitivity in SKBR-3 Cells
    • Ekerljung L, Lennartsson J, Gedda L. The HER2-Binding Affibody Molecule (ZHER2: 342) 2 Increases Radiosensitivity in SKBR-3 Cells. PloS One. 2012; 7 (11): e49579.
    • (2012) PloS One. , vol.7 , Issue.11 , pp. e49579
    • Ekerljung, L.1    Lennartsson, J.2    Gedda, L.3
  • 42
    • 84861682414 scopus 로고    scopus 로고
    • Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis
    • Cao J, Wan S, Tian J, et al. Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis. Contrast Media Mol Imaging. 2012; 7: 390-402.
    • (2012) Contrast Media Mol Imaging. , vol.7 , pp. 390-402
    • Cao, J.1    Wan, S.2    Tian, J.3
  • 43
    • 33644857036 scopus 로고    scopus 로고
    • Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility
    • Albrecht H, DeNardo GL, DeNardo SJ. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. J Immunol Methods. 2006; 310 (1): 100-16.
    • (2006) J Immunol Methods. , vol.310 , Issue.1 , pp. 100-116
    • Albrecht, H.1    DeNardo, G.L.2    DeNardo, S.J.3
  • 44
    • 33644694918 scopus 로고    scopus 로고
    • Novel and simple ELISA-based method for antibody affinity determination
    • Bobrovnik SA, Komisarenko SV, Ilyina LV. Novel and simple ELISA-based method for antibody affinity determination. Ukr Biokhim Zh. 2004, 77 (2): 169-74.
    • (2004) Ukr Biokhim Zh , vol.77 , Issue.2 , pp. 169-174
    • Bobrovnik, S.A.1    Komisarenko, S.V.2    Ilyina, L.V.3
  • 45
    • 0036201921 scopus 로고    scopus 로고
    • Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins
    • Kingshott P, Thissen H, Griesser HJ. Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins. Biomaterials. 2002; 23 (9): 2043-56.
    • (2002) Biomaterials. , vol.23 , Issue.9 , pp. 2043-2056
    • Kingshott, P.1    Thissen, H.2    Griesser, H.J.3
  • 46
    • 0344851745 scopus 로고    scopus 로고
    • Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases
    • Edwards III CK, Martin SW, Seely J, et al. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev. 2003; 55 (10): 1315-36.
    • (2003) Adv Drug Deliv Rev. , vol.55 , Issue.10 , pp. 1315-1336
    • Edwards I.I.I, C.K.1    Martin, S.W.2    Seely, J.3
  • 47
    • 0027077805 scopus 로고
    • Selective labeling of a-or ?-amino groups in peptides by the Bolton-Hunter reagent
    • Gaudriault G, Vincent JP. Selective labeling of a-or ?-amino groups in peptides by the Bolton-Hunter reagent. Peptides. 1992; 13 (6): 1187-92.
    • (1992) Peptides. , vol.13 , Issue.6 , pp. 1187-1192
    • Gaudriault, G.1    Vincent, J.P.2
  • 48
    • 44149088593 scopus 로고    scopus 로고
    • Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT
    • Gainkam LOT, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49 (5): 788-95.
    • (2008) J Nucl Med. , vol.49 , Issue.5 , pp. 788-795
    • Gainkam, L.O.T.1    Huang, L.2    Caveliers, V.3
  • 49
    • 0142123347 scopus 로고    scopus 로고
    • Determination of antibody affinity by ELISA
    • Bobrovnik SA. Determination of antibody affinity by ELISA. Theory. J Biochem Biophys Methods. 2003; 57 (3): 213-36.
    • (2003) Theory. J Biochem Biophys Methods. , vol.57 , Issue.3 , pp. 213-236
    • Bobrovnik, S.A.1
  • 50
    • 0023258208 scopus 로고
    • Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay
    • Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987; (1): 173-9.
    • (1987) J Immunol Methods. , Issue.1 , pp. 173-179
    • Beatty, J.D.1    Beatty, B.G.2    Vlahos, W.G.3
  • 51
    • 0034773992 scopus 로고    scopus 로고
    • The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities
    • Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37: 3-8.
    • (2001) Eur J Cancer. , vol.37 , pp. 3-8
    • Yarden, Y.1
  • 52
    • 32044464123 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (EGFR) signaling in cancer
    • Normanno N, Luca AD, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366: 2-16.
    • (2006) Gene. , vol.366 , pp. 2-16
    • Normanno, N.1    Luca, A.D.2    Bianco, C.3
  • 53
    • 84883489054 scopus 로고    scopus 로고
    • HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling
    • Hartman Z, Zhao H, Agazie YM. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 2013; 32: 4169-80.
    • (2013) Oncogene. , vol.32 , pp. 4169-4180
    • Hartman, Z.1    Zhao, H.2    Agazie, Y.M.3
  • 54
    • 32944459561 scopus 로고    scopus 로고
    • Activation of the Nuclear Factor ?B Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis
    • Emdad L, Sarkar D, Su Z, et al. Activation of the Nuclear Factor ?B Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis. Cancer Res. 2006; 66: 1509-16.
    • (2006) Cancer Res. , vol.66 , pp. 1509-1516
    • Emdad, L.1    Sarkar, D.2    Su, Z.3
  • 55
    • 70349459893 scopus 로고    scopus 로고
    • The Multifaceted Role of MTDH/AEG-1 in Cancer Progression
    • Hu G, Wei Y, Kang Y. The Multifaceted Role of MTDH/AEG-1 in Cancer Progression. Clin Cancer Res. 2009; 15: 5615-20.
    • (2009) Clin Cancer Res. , vol.15 , pp. 5615-5620
    • Hu, G.1    Wei, Y.2    Kang, Y.3
  • 56
    • 33751257780 scopus 로고    scopus 로고
    • Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc
    • Lee S, Su Z, Emdad L, et al. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Prog Nucleic Acid Res Mol Biol. 2006; 103: 17390-5.
    • (2006) Prog Nucleic Acid Res Mol Biol. , vol.103 , pp. 17390-17395
    • Lee, S.1    Su, Z.2    Emdad, L.3
  • 57
    • 0025780991 scopus 로고
    • Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc
    • Denis N, Kitzis A, Kruh J, et al. Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc. Oncogene. 1991; 6: 1453-7.
    • (1991) Oncogene. , vol.6 , pp. 1453-1457
    • Denis, N.1    Kitzis, A.2    Kruh, J.3
  • 58
    • 0035958062 scopus 로고    scopus 로고
    • Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells
    • Sheng H, Shao J, Dubios RN. Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells. J Biol Chem. 2001; 276: 11498-504.
    • (2001) J Biol Chem. , vol.276 , pp. 11498-11504
    • Sheng, H.1    Shao, J.2    Dubios, R.N.3
  • 59
    • 0023726412 scopus 로고
    • Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity
    • Rajagopalan S, Politi PM, Sinha BK, et al. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988; 48 (17): 4766-9.
    • (1988) Cancer Res. , vol.48 , Issue.17 , pp. 4766-4769
    • Rajagopalan, S.1    Politi, P.M.2    Sinha, B.K.3
  • 60
    • 67649872364 scopus 로고    scopus 로고
    • Engineered protein scaffolds as next-generation antibody therapeutics
    • Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. 2009; 13: 245-55.
    • (2009) Curr Opin Chem Biol. , vol.13 , pp. 245-255
    • Gebauer, M.1    Skerra, A.2
  • 61
    • 0037108686 scopus 로고    scopus 로고
    • Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer
    • Kono K, Takahashi A, Ichihara F, et al. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 2002; 62 (20): 5813-7.
    • (2002) Cancer Res. , vol.62 , Issue.20 , pp. 5813-5817
    • Kono, K.1    Takahashi, A.2    Ichihara, F.3
  • 62
    • 34948822890 scopus 로고    scopus 로고
    • EGFR, HER2 and VEGF Pathways
    • Press MF, Lenz HJ. EGFR, HER2 and VEGF Pathways. Drugs. 2007; 67: 2045-75.
    • (2007) Drugs. , vol.67 , pp. 2045-2075
    • Press, M.F.1    Lenz, H.J.2
  • 63
    • 1642422374 scopus 로고    scopus 로고
    • Association with membrane protrusions makes erbB2 an internalization-resistant receptor
    • Hommelgaard AM, Lerdrup M, Deurs B. Association with membrane protrusions makes erbB2 an internalization-resistant receptor. Mol Biol Cell. 2004; 15: 1557-67.
    • (2004) Mol Biol Cell. , vol.15 , pp. 1557-1567
    • Hommelgaard, A.M.1    Lerdrup, M.2    Deurs, B.3
  • 64
    • 0029021518 scopus 로고
    • Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research
    • Earp HS, Dawson TL, Li X, et al. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995; 35: 115-32.
    • (1995) Breast Cancer Res Treat. , vol.35 , pp. 115-132
    • Earp, H.S.1    Dawson, T.L.2    Li, X.3
  • 65
    • 0024456425 scopus 로고
    • Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions
    • Tauchi K, Hori S, Itoh H, et al. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. Virchows Arch. 1989; 416: 65-73.
    • (1989) Virchows Arch. , vol.416 , pp. 65-73
    • Tauchi, K.1    Hori, S.2    Itoh, H.3
  • 66
    • 0028610516 scopus 로고
    • Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma
    • Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol. 1994; 47: 914-9.
    • (1994) J Clin Pathol. , vol.47 , pp. 914-919
    • Dam, P.A.1    Vergote, I.B.2    Lowe, D.G.3
  • 67
    • 84858984798 scopus 로고    scopus 로고
    • The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
    • Luca AD, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012; 16: S17-S27.
    • (2012) Expert Opin Ther Targets. , vol.16 , pp. S17-S27
    • Luca, A.D.1    Maiello, M.R.2    D'Alessio, A.3
  • 68
    • 65549113479 scopus 로고    scopus 로고
    • Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis
    • Yu C, Chen K, Zheng H, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis. 2009; 30: 894-901.
    • (2009) Carcinogenesis. , vol.30 , pp. 894-901
    • Yu, C.1    Chen, K.2    Zheng, H.3
  • 69
    • 0037139394 scopus 로고    scopus 로고
    • Efficient tumor targeting by single-domain antibody fragments of camels
    • Cortez-Retamozo V, Lauwereys M, Gobert M, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002; 98 (3): 456-62.
    • (2002) Int J Cancer. , vol.98 , Issue.3 , pp. 456-462
    • Cortez-Retamozo, V.1    Lauwereys, M.2    Gobert, M.3
  • 70
    • 0030224856 scopus 로고    scopus 로고
    • Multiple affinity domains for the detection, purification and immobilization of recombinant proteins
    • Nilsson J, Larsson M, Stahl S, et al. Multiple affinity domains for the detection, purification and immobilization of recombinant proteins. J Mol Recognit. 1996; (5-6): 585-94.
    • (1996) J Mol Recognit. , Issue.5-6 , pp. 585-594
    • Nilsson, J.1    Larsson, M.2    Stahl, S.3
  • 71
    • 0031259833 scopus 로고    scopus 로고
    • Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins
    • Nilsson J, Ståhl S, Lundeberg J, et al. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr Purif. 1997, 11 (1): 1-16.
    • (1997) Protein Expr Purif , vol.11 , Issue.1 , pp. 1-16
    • Nilsson, J.1    Ståhl, S.2    Lundeberg, J.3
  • 72
    • 0033580768 scopus 로고    scopus 로고
    • Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation
    • He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 1999; 65 (4): 355-68.
    • (1999) Life Sci. , vol.65 , Issue.4 , pp. 355-368
    • He, X.H.1    Shaw, P.C.2    Tam, S.C.3
  • 73
    • 79958167185 scopus 로고    scopus 로고
    • Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models
    • Ledón N, Casacó A, Casanova E, et al. Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models. Placenta. 2011; 32 (7): 531-4.
    • (2011) Placenta. , vol.32 , Issue.7 , pp. 531-534
    • Ledón, N.1    Casacó, A.2    Casanova, E.3
  • 74
    • 84915751470 scopus 로고    scopus 로고
    • Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
    • Dokter W, Ubink R, van der Lee M, et al. Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform. Mol Cancer Ther; 2014, 13 (11): 2618-29.
    • (2014) Mol Cancer Ther , vol.13 , Issue.11 , pp. 2618-2629
    • Dokter, W.1    Ubink, R.2    van der Lee, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.